Stock IBRX IMMUNITYBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
8.26 USD +5.76% Intraday chart for ImmunityBio, Inc. +3.38% +64.54%
May. 07 ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment MT
May. 06 Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline MT

Evolution of the average Target Price on ImmunityBio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5e.YbkCJW_wNjuWUVC7V1MVp1iPi5sDf9_n9iJ5wkadqUw.OelzSgmUUGriBAHVYmJ3zCD4-MtaEImhx1NOlST57wYmjkR8HbMOFt1lZA~0bcaabe6860080a4c1398ff9750934e3

Analyst Recommendations on ImmunityBio, Inc.

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance MT
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating MT
Piper Sandler Downgrades ImmunityBio to Neutral From Overweight, Cuts Price Target to $4 From $10 MT
Jefferies Starts ImmunityBio at Buy With $8 Price Target MT
Piper Sandler Adjusts ImmunityBio's Price Target to $10 From $20, Reiterates Overweight Rating MT
ImmunityBio : Says Phase 2/3 Trial in BCG-Unresponsive Bladder Cancer Patients Achieves Complete Response Rate of 72% MT
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial CI
Nantkwest : Reports Positive Interim Data on Survival Rates from Pivotal Pancreatic Cancer Trials; Shares Hit New 52-Week High MT
NantKwest, Inc. and ImmunityBio, Inc. Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials CI
ImmunityBio, Inc. Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.26 USD
Average target price
7.5 USD
Spread / Average Target
-9.20%
High Price Target
9 USD
Spread / Highest target
+8.96%
Low Price Target
6 USD
Spread / Lowest Target
-27.36%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ImmunityBio, Inc.

Piper Sandler
Jefferies & Co.

Ratings for ImmunityBio, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. Consensus ImmunityBio, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW